Merus Labs is an international specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. The Company leverages its expertise and scalable platform in Europe, Canada and select other markets to deliver value. Merus Labs is listed on the Toronto Stock Exchange (MSL) and NASDAQ (MSLI).
Norgine B.V. completes acquisition of Merus Labs International Inc. strengthening its leading position in the European specialist pharma market
Merus Labs International Inc. and Norgine B.V. receive Spanish anti-trust approval of proposed Arrangement of Fiscal Q1 2017 Earnings Release
Merus Labs International Inc. Mails Letter to Shareholders with Reminder to Vote FOR the Proposed Arrangement with Norgine B.V. by deadline of 10:00 AM (Toronto time) July 6, 2017, and Receives Positive Recommendation in Favour of the Arrangement from Independent Proxy Advisor ISS